RYTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rhythm Pharmaceuticals Inc (RYTM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent FDA approvals, strong analyst ratings with upward price target revisions, and robust revenue growth make it a compelling opportunity. Despite hedge fund selling, the stock's technical indicators and options data suggest stability and potential upside.
The MACD is positive and contracting, indicating a potential upward trend. RSI is neutral at 40.172, showing no overbought or oversold conditions. The stock is trading near its pivot level of 86.787, with key resistance at 89.778 and support at 83.796, suggesting a balanced risk-reward scenario.
FDA approval for Imcivree to treat acquired hypothalamic obesity, expanding its commercial potential.
Strong revenue growth of 36.87% YoY in Q4
Analysts have raised price targets significantly, with the highest target at $
Gross margin improvement to 91.61%.
Hedge funds have significantly increased selling activity, up 288.14% last quarter.
No recent news or congress trading data to provide additional sentiment support.
Insider trading trends are neutral, showing no strong insider confidence.
In Q4 2025, Rhythm Pharmaceuticals reported revenue growth of 36.87% YoY to $57.25M. Net income improved by 9.42% YoY to -$48.84M, and EPS increased by 1.39% YoY to -$0.73. Gross margin rose slightly to 91.61%, indicating strong operational efficiency despite ongoing losses.
Analysts are overwhelmingly positive on RYTM, with multiple firms raising price targets recently. RBC Capital raised its target to $136, H.C. Wainwright to $105, BofA to $149, Citizens to $155, and Citi to $142. The consensus reflects confidence in the company's growth potential, particularly following FDA approvals.
